Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Trovagene Inc (TROV)

Trovagene Inc (TROV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Trovagene Inc 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 USA

www.trovagene.com P: 858-952-7570

Description:

Trovagene is a clinical-stage, oncology therapeutics company, taking a precision cancer medicine approach to develop drugs that target mitosis (cell division) to treat various types of cancer, including leukemias, lymphomas and solid tumors. Trovagene has intellectual property and proprietary technology that enables the Company to analyze circulating tumor DNA (ctDNA) and clinically actionable markers to identify patients most likely to respond to specific cancer therapies. Trovagene plans to continue to vertically integrate its tumor genomics technology with the development of targeted cancer therapeutics.

Key Statistics

Overview:

Market Capitalization, $K 13,103
Shares Outstanding, K 11,011
Annual Sales, $ 240 K
Annual Net Income, $ -16,410 K
Last Quarter Sales, $ 90 K
Last Quarter Net Income, $ -4,240 K
60-Month Beta 1.04
% of Insider Shareholders 0.60%
% of Institutional Shareholders 9.99%
Float, K 10,945
% Float 99.40%

Growth:

1-Year Return -64.90%
3-Year Return -97.88%
5-Year Return -99.85%
5-Year Revenue Growth -14.29%
5-Year Earnings Growth 95.91%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 05/12/20
Earnings Per Share ttm -3.03
EPS Growth vs. Prev Qtr 28.17%
EPS Growth vs. Prev Year 53.21%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-6 on 02/20/19

TROV Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -202.00%
Return-on-Assets % -122.92%
Profit Margin % -6,837.50%
Debt/Equity 0.12
Price/Sales 53.93
Price/Cash Flow N/A
Price/Book 1.26
Book Value/Share 0.94
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar